Loading
Expert Witness Insights by Area of Expertise
7 min read
Areas of Expertise :
Pharmacology, Medical Toxicology, Toxicology, Drugs
Published Date:
Last Modified Date:
Pharmacology expert witnesses help evaluate whether medication effects, drug interactions, dosage, metabolism, and documented exposure support a proposed causal relationship in drug-related injury litigation. This article explains how experts assess pharmacokinetics, pharmacodynamics, interaction risks, general and specific causation, drug concentration results, adverse event data, and the reliability of pharmacology opinions under Federal Rule of Evidence 702.
Drug-related injury litigation may involve disputes over adverse medication effects, drug interactions, or whether a particular exposure contributed to a patient's condition. A known side effect or symptoms appearing soon after medication use do not, by themselves, establish causation.
A pharmacology expert witness may evaluate drug mechanisms, dose-response relationships, medication interactions, and evidence about a possible connection between drug exposure and an alleged injury. The scope of the opinion depends on the expert's qualifications and the scientific or clinical issues presented.
This guide explains how pharmacology experts assess drug interactions, causation evidence, and the limits of expert testimony.
Pharmacology experts evaluate how medications interact with biological systems and whether those effects are relevant to a disputed injury. Two areas of pharmacology help explain these effects.
Pharmacokinetics concerns drug absorption, distribution, metabolism, and excretion. These processes affect drug concentrations and may explain altered exposure, accumulation, or toxicity.
A pharmacology expert may examine:
Medication dosage, administration route, and treatment duration.
Drug metabolism and elimination characteristics.
Kidney or liver function affecting drug exposure.
Concurrent medications that may alter drug concentrations.
Laboratory measurements and their relationship to the alleged exposure.
The National Library of Medicine explains that blood concentrations of certain medications change over time and can be influenced by illness, aging, and other medications.
Pharmacodynamics concerns a drug's biological effects, including interactions with receptors, enzymes, and physiological systems.
An expert may examine whether a medication's known effects, including possible combined effects with other drugs, are consistent with the alleged injury.
A plausible pharmacological mechanism supports further investigation but does not independently establish patient-specific causation.
Drug interactions
Pharmacokinetics
Pharmacodynamics
Adverse Event
Drug Labels
Drug Regulation
Pharmaceutical Product Liability
Drug-related injury litigation may involve disputes over adverse medication effects, drug interactions, or whether a particular exposure contributed to a patient's condition. A known side effect or symptoms appearing soon after medication use do not, by themselves, establish causation.
A pharmacology expert witness may evaluate drug mechanisms, dose-response relationships, medication interactions, and evidence about a possible connection between drug exposure and an alleged injury. The scope of the opinion depends on the expert's qualifications and the scientific or clinical issues presented.
This guide explains how pharmacology experts assess drug interactions, causation evidence, and the limits of expert testimony.
Pharmacology experts evaluate how medications interact with biological systems and whether those effects are relevant to a disputed injury. Two areas of pharmacology help explain these effects.
Pharmacokinetics concerns drug absorption, distribution, metabolism, and excretion. These processes affect drug concentrations and may explain altered exposure, accumulation, or toxicity.
A pharmacology expert may examine:
Medication dosage, administration route, and treatment duration.
Drug metabolism and elimination characteristics.
Kidney or liver function affecting drug exposure.
Concurrent medications that may alter drug concentrations.
Laboratory measurements and their relationship to the alleged exposure.
The National Library of Medicine explains that blood concentrations of certain medications change over time and can be influenced by illness, aging, and other medications.
Pharmacodynamics concerns a drug's biological effects, including interactions with receptors, enzymes, and physiological systems.
An expert may examine whether a medication's known effects, including possible combined effects with other drugs, are consistent with the alleged injury.
A plausible pharmacological mechanism supports further investigation but does not independently establish patient-specific causation.
Drug interactions may change medication exposure, therapeutic effectiveness, or adverse-effect risk. Their relevance to litigation depends on the medications involved and the patient's actual exposure.
Pharmacokinetic interactions occur when one medication changes how another is absorbed, distributed, metabolized, or eliminated.
The U.S. Food and Drug Administration's (FDA) August 2024 M12 Drug Interaction Studies guidance provides nonbinding recommendations for evaluating enzyme- and transporter-mediated pharmacokinetic drug interactions during drug development. It does not, by itself, determine the applicable standard of care in litigation.
Pharmacodynamic interactions occur when medications influence one another's biological effects.
For example, opioids and benzodiazepines can produce combined central nervous system depression. In 2016, the FDA required boxed warnings and other labeling changes for prescription opioid analgesics, opioid-containing cough products, and benzodiazepines. The changes addressed the risks of using these medications together, including profound sedation, respiratory depression, coma, and death.
A suitably qualified expert may assess whether these recognized risks are consistent with the clinical findings, medication timing, and possible exposure to other substances in a particular case.
Drug-related causation analysis addresses two questions: whether a medication can cause the type of injury alleged and whether it caused or contributed to the patient's condition.
General causation concerns whether a medication or interaction can cause the type of injury alleged. Relevant evidence may include clinical trials, epidemiological research, laboratory studies, and biological mechanisms.
Specific causation addresses whether the exposure caused or contributed to the alleged injury in an individual patient.
The Reference Manual on Scientific Evidence, Fourth Edition explains the distinction and the limitations of applying population-based research to individual causation questions.
Experts assessing patient-specific causation may examine when medication use began, dosage changes, symptom onset, and whether the timeline is consistent with the proposed mechanism.
Experts may examine whether symptoms improved after stopping a suspected medication (dechallenge). If subsequent reexposure occurred (rechallenge), they may also assess whether symptoms recurred. These observations require clinical interpretation and are not conclusive individually. Rechallenge is rarely ethically justified when assessing a suspected adverse drug reaction.
For suspected drug-induced liver injury, the National Institutes of Health's LiverTox resource describes the Roussel Uclaf Causality Assessment Method (RUCAM), which considers exposure timing, clinical course, competing causes, and other evidence. RUCAM scores help assess the likelihood that a particular medication caused liver injury, but they do not, by themselves, establish legal causation.
Alternative explanations may include underlying disease, other medications, or unrelated medical conditions. A causation opinion should address material competing explanations and uncertainties.
The materials a pharmacology expert reviews depend on the alleged injury, disputed exposure, and proposed pharmacological mechanism. Relevant evidence may include:
Medication records: Prescriptions, pharmacy histories, administration records, and dosage changes.
Clinical records: Physician notes, hospital findings, diagnoses, and treatment histories.
Laboratory evidence: Drug concentrations, toxicology findings, and relevant organ function tests.
Scientific and regulatory materials: Drug-interaction studies, clinical research, prescribing information, and safety communications.
Litigation materials: Witness testimony and records concerning actual medication use or exposure.
The FDA's Drugs@FDA database provides regulatory history and FDA-approved prescribing information for covered products. DailyMed provides submitted labeling, which may differ from the most recently FDA-approved version.
For historical claims, counsel should identify the labeling and scientific information relevant to the disputed period.
Drug concentration measurements can help experts assess exposure. Interpreting those results depends on specimen type, collection timing and handling, testing methods, and the patient's clinical circumstances. A measured concentration does not necessarily establish the physiological effect experienced by a patient.
Reports in the FDA's Adverse Event Monitoring System (AEMS) may identify potential safety concerns, but they can be incomplete or duplicated and cannot independently establish causation or adverse-event incidence.
Experts should evaluate these materials alongside the broader scientific evidence and patient-specific findings.
Pharmacologists may address drug mechanisms and interactions. Depending on the disputed issue and their qualifications, clinical pharmacists may evaluate medication practices, medical toxicologists or physicians may address toxic effects and clinical findings, and epidemiologists may analyze population-based evidence.
Courts look at whether an expert's qualifications fit the specific opinions offered.
In proceedings governed by the Federal Rules of Evidence, Rule 702 requires the proponent to show the court, by a more-likely-than-not standard, that its admissibility requirements are met.
The expert's specialized knowledge must help the trier of fact understand the evidence or determine a fact in issue. The testimony must be based on sufficient facts or data and be the product of reliable principles and methods. The expert's opinion must also reflect a reliable application of the principles and methods to the facts of the case. The amendment to Rule 702 took effect on December 1, 2023.
Attorneys should examine an expert's qualifications, underlying data, methodology, assumptions, and treatment of contrary evidence. In state-court proceedings, attorneys should verify the applicable expert-testimony admissibility requirements.
Can a pharmacology expert determine whether a medication caused a specific injury?
A suitably qualified pharmacology expert may evaluate whether drug effects and documented exposure support a proposed causal explanation. Clinical diagnosis and patient-specific causation may require additional medical expertise.
Can prescribed medications cause harmful drug interactions?
Yes. Certain prescribed medications, including opioids and benzodiazepines, carry recognized risks when used together. Whether an interaction contributed to an injury requires assessment of the patient's exposure and clinical findings.
Does a reported adverse event establish causation?
No. Reporting an adverse event does not establish that a medication caused it. Assessing a proposed causal relationship involves considering the available scientific evidence, medication history, clinical findings, and reasonable alternative explanations.
Can pharmacology experts interpret blood drug concentration results?
Suitably qualified experts may interpret drug concentrations in relation to dosage, sampling time, metabolism, and expected effects. Clinical or forensic toxicology expertise may also be necessary.
Drug interactions may change medication exposure, therapeutic effectiveness, or adverse-effect risk. Their relevance to litigation depends on the medications involved and the patient's actual exposure.
Pharmacokinetic interactions occur when one medication changes how another is absorbed, distributed, metabolized, or eliminated.
The U.S. Food and Drug Administration's (FDA) August 2024 M12 Drug Interaction Studies guidance provides nonbinding recommendations for evaluating enzyme- and transporter-mediated pharmacokinetic drug interactions during drug development. It does not, by itself, determine the applicable standard of care in litigation.
Pharmacodynamic interactions occur when medications influence one another's biological effects.
For example, opioids and benzodiazepines can produce combined central nervous system depression. In 2016, the FDA required boxed warnings and other labeling changes for prescription opioid analgesics, opioid-containing cough products, and benzodiazepines. The changes addressed the risks of using these medications together, including profound sedation, respiratory depression, coma, and death.
A suitably qualified expert may assess whether these recognized risks are consistent with the clinical findings, medication timing, and possible exposure to other substances in a particular case.
Drug-related causation analysis addresses two questions: whether a medication can cause the type of injury alleged and whether it caused or contributed to the patient's condition.
General causation concerns whether a medication or interaction can cause the type of injury alleged. Relevant evidence may include clinical trials, epidemiological research, laboratory studies, and biological mechanisms.
Specific causation addresses whether the exposure caused or contributed to the alleged injury in an individual patient.
The Reference Manual on Scientific Evidence, Fourth Edition explains the distinction and the limitations of applying population-based research to individual causation questions.
Experts assessing patient-specific causation may examine when medication use began, dosage changes, symptom onset, and whether the timeline is consistent with the proposed mechanism.
Experts may examine whether symptoms improved after stopping a suspected medication (dechallenge). If subsequent reexposure occurred (rechallenge), they may also assess whether symptoms recurred. These observations require clinical interpretation and are not conclusive individually. Rechallenge is rarely ethically justified when assessing a suspected adverse drug reaction.
For suspected drug-induced liver injury, the National Institutes of Health's LiverTox resource describes the Roussel Uclaf Causality Assessment Method (RUCAM), which considers exposure timing, clinical course, competing causes, and other evidence. RUCAM scores help assess the likelihood that a particular medication caused liver injury, but they do not, by themselves, establish legal causation.
Alternative explanations may include underlying disease, other medications, or unrelated medical conditions. A causation opinion should address material competing explanations and uncertainties.
The materials a pharmacology expert reviews depend on the alleged injury, disputed exposure, and proposed pharmacological mechanism. Relevant evidence may include:
Medication records: Prescriptions, pharmacy histories, administration records, and dosage changes.
Clinical records: Physician notes, hospital findings, diagnoses, and treatment histories.
Laboratory evidence: Drug concentrations, toxicology findings, and relevant organ function tests.
Scientific and regulatory materials: Drug-interaction studies, clinical research, prescribing information, and safety communications.
Litigation materials: Witness testimony and records concerning actual medication use or exposure.
The FDA's Drugs@FDA database provides regulatory history and FDA-approved prescribing information for covered products. DailyMed provides submitted labeling, which may differ from the most recently FDA-approved version.
For historical claims, counsel should identify the labeling and scientific information relevant to the disputed period.
Drug concentration measurements can help experts assess exposure. Interpreting those results depends on specimen type, collection timing and handling, testing methods, and the patient's clinical circumstances. A measured concentration does not necessarily establish the physiological effect experienced by a patient.
Reports in the FDA's Adverse Event Monitoring System (AEMS) may identify potential safety concerns, but they can be incomplete or duplicated and cannot independently establish causation or adverse-event incidence.
Experts should evaluate these materials alongside the broader scientific evidence and patient-specific findings.
Pharmacologists may address drug mechanisms and interactions. Depending on the disputed issue and their qualifications, clinical pharmacists may evaluate medication practices, medical toxicologists or physicians may address toxic effects and clinical findings, and epidemiologists may analyze population-based evidence.
Courts look at whether an expert's qualifications fit the specific opinions offered.
In proceedings governed by the Federal Rules of Evidence, Rule 702 requires the proponent to show the court, by a more-likely-than-not standard, that its admissibility requirements are met.
The expert's specialized knowledge must help the trier of fact understand the evidence or determine a fact in issue. The testimony must be based on sufficient facts or data and be the product of reliable principles and methods. The expert's opinion must also reflect a reliable application of the principles and methods to the facts of the case. The amendment to Rule 702 took effect on December 1, 2023.
Attorneys should examine an expert's qualifications, underlying data, methodology, assumptions, and treatment of contrary evidence. In state-court proceedings, attorneys should verify the applicable expert-testimony admissibility requirements.
Can a pharmacology expert determine whether a medication caused a specific injury?
A suitably qualified pharmacology expert may evaluate whether drug effects and documented exposure support a proposed causal explanation. Clinical diagnosis and patient-specific causation may require additional medical expertise.
Can prescribed medications cause harmful drug interactions?
Yes. Certain prescribed medications, including opioids and benzodiazepines, carry recognized risks when used together. Whether an interaction contributed to an injury requires assessment of the patient's exposure and clinical findings.
Does a reported adverse event establish causation?
No. Reporting an adverse event does not establish that a medication caused it. Assessing a proposed causal relationship involves considering the available scientific evidence, medication history, clinical findings, and reasonable alternative explanations.
Can pharmacology experts interpret blood drug concentration results?
Suitably qualified experts may interpret drug concentrations in relation to dosage, sampling time, metabolism, and expected effects. Clinical or forensic toxicology expertise may also be necessary.
Drug interactions
Pharmacokinetics
Pharmacodynamics
Adverse Event
Drug Labels
Drug Regulation
Pharmaceutical Product Liability
Expert Witness Insights by Area of Expertise
Expert Witness Insights by Area of Expertise